Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks

Here are 10 big pharma and big biotech cancer immunotherapy stocks.


10 Big Pharma and Biotech Cancer Immunotherapy Stocks

Stock Returns & Price Chart

Symbol

Recent Prices &
Annualized Return

AmgenAMGN
AstraZenecaAZN
Bristol-Myers SquibbBMY
CelgeneCELG
Gilead SciencesGILD
Incyte CorporationINCY
MerckMRK
Nektar TherapeuticsNKTR
NovartisNVS
PfizerPFE
Price data from Quandl as of most recent close.

To inspect the performance of the Big Pharma and Biotech Cancer Immunotherapy Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.

All 10 stocks are included in the portfolio computations. The current value of the portfolio assumes that $1,000.00 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends.

The current value of a $10,000 investment is $41,248. The percent return is 312.48%. The annualized return is 15.22%.




Return Summary for Big Pharma and Biotech Cancer Immunotherapy Stocks
Start DateAug-31-2009
Start Investment$10,000.00
End DateAug-23-2019
Current Value of Investment$41,248.25
Total Return312.48%
Annualized Return15.22%
Min DateOct-30-2009
Min Price$9,758.35
Max DateMar-29-2018
Max Price$49,669.29
# Values121
Number Returns7,260
Number Profitable Returns6,497
Percent Profitable Returns89.49%
Number Unprofitable Returns763
Percent Unprofitable Returns10.51%
Profitable to Unprofitable Returns Ratio8.52



NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.


Related Portfolios

Portfolio of Biotech Stocks

Portfolio of Cancer Immunotherapy Stocks

Portfolio of Immune Checkpoint Inhibitor Stocks